Elite Pharmaceuticals Files 8-K on Financials

TL;DR

Elite Pharma dropped an 8-K on financials, check it out.

AI Summary

Elite Pharmaceuticals, Inc. filed an 8-K on August 14, 2025, reporting on its Results of Operations and Financial Condition. The filing also included Regulation FD Disclosures and Financial Statements and Exhibits. The company, incorporated in Nevada with its principal executive offices in Northvale, New Jersey, previously operated under the name Elite Pharmaceuticals Inc. /DE/.

Why It Matters

This 8-K filing provides crucial updates on Elite Pharmaceuticals' financial performance and operational status, which can influence investor decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• ELITE PHARMACEUTICALS, INC. (company) — Registrant
• ELITE PHARMACEUTICALS INC /NV/ (company) — Exact name of registrant
• Nevada (jurisdiction) — State of incorporation
• 165 Ludlow Avenue, Northvale, New Jersey 07647 (location) — Address of principal executive offices
• 201-750-2646 (phone_number) — Registrant's telephone number
• ELITE PHARMACEUTICALS INC /DE/ (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 2.02. R

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 14KB
• ex99-1_001.jpg (GRAPHIC) — 9KB
• 0001641172-25-024088.txt ( ) — 230KB
• eltp-20250814.xsd (EX-101.SCH) — 3KB
• eltp-20250814_lab.xml (EX-101.LAB) — 33KB
• eltp-20250814_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC . ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 2.02. Results of Operations and Financial Condition. On August 14, 2025, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") filed its quarterly report on Form 10-Q for the quarter ended June 30, 2025 of fiscal year 2026, and, thereafter, issued a press release announcing its financial results for that fiscal year. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As noted in the press release, the Company will host a conference call at 11:30 AM Eastern Daylight Time (EDT) on Friday, August 15, 2025, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call. Conference Call Information Date: August 15, 2025 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840 Questions: dianne@elitepharma.com Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 Audio Replay: https://elite.irpass.com/events_presentations Item 7.01 Regulation FD Disclosure. The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 14, 2025 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO

View Full Filing

View this 8-K filing on SEC EDGAR